Pfizer reports positive results from Echelon-3 study
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
There was no observation related to data integrity reported
Subscribe To Our Newsletter & Stay Updated